Gainers

• Cellectis (NASDAQ:CLLS) stock increased by 17.1% to $3.5 during Tuesday's after-market session. The company's market cap stands at $294.7 million.
• Context Therapeutics (NASDAQ:CNTX) shares moved upwards by 8.55% to $1.65. The company's market cap stands at $157.1 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) shares rose 7.1% to $0.33. The company's market cap stands at $8.6 million.
• Pomdoctor (NASDAQ:POM) stock increased by 6.74% to $0.12. The company's market cap stands at $13.3 million.
• 60 Degrees (NASDAQ:SXTP) shares increased by 6.47% to $1.48. The market value of their outstanding shares is at $3.8 million.
• Genenta Science (NASDAQ:GNTA) shares increased by 6.24% to $1.7. The company's market cap stands at $42.1 million.

Losers

• Picard Medical (AMEX:PMI) shares fell 16.6% to $0.27 during Tuesday's after-market session. The market value of their outstanding shares is at $24.6 million.
• Scinai Immunotherapeutics (NASDAQ:SCNI) stock declined by 15.33% to $0.3. The market value of their outstanding shares is at $1.6 million.
• VolitionRX (AMEX:VNRX) shares decreased by 8.83% to $1.24. The market value of their outstanding shares is at $11.5 million.
• Summit Therapeutics (NASDAQ:SMMT) stock decreased by 8.68% to $13.05. The market value of their outstanding shares is at $10.9 billion.
• Universe Pharmaceuticals (NASDAQ:UPC) stock decreased by 8.61% to $3.08. The company's market cap stands at $2.0 million.
• Actuate Therapeutics (NASDAQ:ACTU) shares declined by 7.97% to $1.85. The market value of their outstanding shares is at $43.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.